

Section 1 - 125742/0/0

0001 --> 125742/0.0 (Original Application) - Recd 2021-05-06 - DATS# 1067058

- 1 Administrative Information and Prescribing Information
  - [0001] USA (v3.3)
    - 1.1 Forms
      - 1.1.2 FDA 356h: Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use
        - [0001] (356h) Initial BLA - Roll 1
      - 1.1.3 FDA 3397: User Fee Cover Sheet
        - [0001] (3397) User Fee Cover Sheet
      - 1.1.7 FDA 3674: Certification of Compliance
        - [0001] (3674) Initial BLA
    - 1.2 Cover Letters
      - [0001] (CL) Initial BLA - Roll 1
      - [0001] Priority Review Request
    - 1.3 Administrative Information
      - 1.3.1 Contact/sponsor/applicant Information
        - 1.3.1.4 Transfer of Obligation
          - [0001] Transfer of Obligation
      - 1.3.3 Debarment Certification
        - [0001] Debarment Certification
      - 1.3.4 Financial Certification and Disclosure

- ▲  1.3.4 Financial Certification and Disclosure
  -  [0001] Financial Certification and Disclosure - Summary Note
  -  [0001] Financial Certification and Disclosure - Bias Statement
  -  [0001] Financial Certification and Disclosure - FDA Form 3454
  -  [0001] Financial Certification and Disclosure - FDA Form 3455
- ▲  1.3.5 Patent and Exclusivity
  - ▲  1.3.5.3 Exclusivity Claim
    -  [0001] Exclusivity Claim
- ▲  1.4 References
  - ▲  1.4.3 List of Authorized Persons to Incorporate By Reference
    -  [0001] Letter of Authorization to US Agent
- ▲  1.6 Meetings
  - ▲  1.6.3 Correspondence Regarding Meetings
    -  [0001] Correspondence Regarding Meetings
- ▲  1.7 Fast Track
  - ▲  1.7.4 Correspondence Regarding Fast Track/Rolling Review
    -  [0001] Grant Fast Track Designation Letter
- ▲  1.9 Pediatric Administrative Information
  - ▲  1.9.2 Request for Deferral of Pediatric Studies
    -  [0001] Request for Deferral of Pediatric Studies
  - ▲  1.9.4 Proposed Pediatric Study Request and Amendments
    -  [0001] Agreed Initial Pediatric Study Plan

- ▲  1.9.4 Proposed Pediatric Study Request and Amendments
  -  [0001] Agreed Initial Pediatric Study Plan
- ▲  1.9.6 Other Correspondence Regarding Pediatric Exclusivity or Study Plans
  -  [0001] Agreed iPSP Agreement Letter
- ▲  1.12 Other Correspondence
  - ▲  1.12.5 Request for a Waiver
    -  [0001] Waiver Request for FDA Designated Suffix
- ▶  2 Common Technical Document Summaries
- ▶  **4 Nonclinical Study Reports**
- ▶  5 Clinical Study Reports

Section 2 - 125742/0/0

- ▲ 1.12 Other Correspondence
  - ▲ 1.12.5 Request for a Waiver
    - ▲ [0001] Waiver Request for FDA Designated Suffix
- ▲ 2 Common Technical Document Summaries
  - ▲ 2.2 Introduction
    - ▲ [0001] Introduction
  - ▲ 2.4 Nonclinical Overview
    - ▲ [0001] Nonclinical Overview
  - ▲ 2.5 Clinical Overview
    - ▲ [0001] Clinical Overview
  - ▲ 2.6 Nonclinical Written and Tabulated Summaries
    - ▲ 2.6.1 Introduction
      - ▲ [0001] Introduction
    - ▲ 2.6.2 Pharmacology Written Summary
      - ▲ [0001] Pharmacology Written Summary
    - ▲ 2.6.3 Pharmacology Tabulated Summary
      - ▲ [0001] Pharmacology Tabulated Summary
    - ▲ 2.6.4 Pharmacokinetics Written Summary
      - ▲ [0001] Pharmacokinetics Written Summary
    - ▲ 2.6.5 Pharmacokinetics Tabulated Summary
      - ▲ [0001] Pharmacokinetics Tabulated Summary
    - ▲ 2.6.6 Toxicology Written Summary

- ▶  [0001] Pharmacology Tabulated Summary
- ▶  2.6.4 Pharmacokinetics Written Summary
  - ▶  [0001] Pharmacokinetics Written Summary
- ▶  2.6.5 Pharmacokinetics Tabulated Summary
  - ▶  [0001] Pharmacokinetics Tabulated Summary
- ▶  2.6.6 Toxicology Written Summary
  - ▶  [0001] Toxicology Written Summary
- ▶  2.6.7 Toxicology Tabulated Summary
  - ▶  [0001] Toxicology Tabulated Summary
- ▶  2.7 Clinical Summary
  - ▶  2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
    - ▶  [0001] Summary of Biopharmaceutic Studies and Associated Analytical Methods
  - ▶  2.7.3 Summary of Clinical Efficacy
    - ▶  [0001] Summary of Clinical Efficacy
  - ▶  2.7.4 Summary of Clinical Safety
    - ▶  [0001] Summary of Clinical Safety
  - ▶  2.7.5 Literature-References
    - ▶  [0001] Literature References
  - ▶  2.7.6 Synopses of Individual Studies
    - ▶  [0001] Synopses of Individual Studies

▶  **4 Nonclinical Study Reports**

▶  **5 Clinical Study Reports**

## Section 4 - 125742/0/0

4	Nonclinical Study Reports
4.2	Study Reports
4.2.1	Pharmacology
4.2.1.1	Primary Pharmacodynamics
[0001]	R-20-0085 - COVID-19: Immunogenicity Study of the LNP-Formulated modRNA Encoding the viral S Protein-V9
[0001]	R-20-0112 - Characterizing the Immunophenotype in Spleen and Lymph Node of Mice Treated with SARS-CoV-2 Vaccine Candidates
[0001]	R-20-0211 - In vitro Expression of BNT162b2 Drug Substance and Drug Product
[0001]	VR-VTR-10671 - BNT162b2 (V9) Immunogenicity and Evaluation of Protection against SARS-CoV-2 Challenge in Rhesus Macaques
[0001]	VR-VTR-10741 - Structural and Biophysical Characterization of SARS-CoV-2 Spike Glycoprotein (P2 S) as a Vaccine Antigen
4.2.2	Pharmacokinetics
4.2.2.2	Absorption
[0001]	072424 - A Single Dose Pharmacokinetics Study of ALC-0315 and ALC-0159 Following Intravenous Bolus Injection of PF-07302048 Nanoparticle Formulation in Wistar Han Rats
4.2.2.3	Distribution
[0001]	R-20-0072 - Expression of Luciferase-Encoding ModRNA After I.M. Application of GMP-Ready <b>(b) (4)</b> NP Formulation
[0001]	185350 - A Tissue Distribution Study of a [3H]-Labelled Lipid Nanoparticle-mRNA Formulation Containing ALC-0315 and ALC-0159 Following Intramuscular Administration in Wistar Han Rats
4.2.2.4	Metabolism
[0001]	01049-20008 - In Vitro Metabolic Stability of ALC-0315 in CD-1/ICR Mouse, Sprague Dawley Rat, Wistar Han Rat, Cynomolgus Monkey, and Human Liver Microsomes
[0001]	01049-20009 - In Vitro Metabolic Stability of ALC-0315 in CD-1/ICR Mouse, Sprague Dawley Rat, Cynomolgus Monkey, and Human Liver S9 Fractions
[0001]	01049-20010 - In Vitro Metabolic Stability of ALC-0315 in CD-1/ICR Mouse, Sprague Dawley Rat, Wistar Han Rat, Cynomolgus Monkey, and Human Hepatocytes
[0001]	01049-20020 - In Vitro Metabolic Stability of ALC-0159 in CD-1/ICR Mouse, Sprague Dawley Rat, Wistar Han Rat, Cynomolgus Monkey, and Human Liver Microsomes
[0001]	01049-20021 - In Vitro Metabolic Stability of ALC-0159 in CD-1/ICR Mouse, Sprague Dawley Rat, Cynomolgus Monkey, and Human Liver S9 Fractions
[0001]	01049-20022 - In Vitro Metabolic Stability of ALC-0159 in CD-1/ICR Mouse, Sprague Dawley Rat, Wistar Han Rat, Cynomolgus Monkey, and Human Hepatocytes
[0001]	043725 - Investigation of the Biotransformation of ALC-0159 and ALC-0315 In Vitro and In Vivo in Rats
4.2.3	Toxicology
4.2.3.2	Repeat-Dose Toxicity
[0001]	38166 - Repeat-Dose Toxicity Study of Three LNP-Formulated RNA Platforms Encoding for Viral Proteins By Repeated Intramuscular Administration to Wistar Han Rats
[0001]	20GR142 - 17-Day Intramuscular Toxicity Study of BNT162b2 (V9) and BNT162b3c in Wistar Han Rats with a 3-Week Recovery
4.2.3.5	Reproductive and Developmental Toxicity
4.2.3.5.1	Fertility and early embryonic development
[0001]	2026434 - Combined Fertility and Developmental Study (Including Teratogenicity and Prenatal Investigations) of BNT162b1, BNT162b2 and BNT162b2 by the Intramuscular Route in the Wistar Rat GLP Study
4.3	Literature References
4.3	Literature References
[0001]	Al-Amri SS, Abbas AT, Siddiq LA, et al. Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. <i>Sci Rep</i> 2017;7:44875
[0001]	Bany MA, May S, Weaver EA. Imaging luciferase-expressing viruses. <i>Methods Mol Biol</i> 2012; 797:79-87.
[0001]	Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. <i>Science</i> 2020; :First release
[0001]	Berger Rentsch M, Zimmer G. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. <i>PLoS One</i> 2011; 6(10):e25858
[0001]	Boone L, Meyer D, Cusick P, et al. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. <i>Vet Clin Pathol.</i> 2005;34(3):182-188.
[0001]	Brouwer PJM, Caniële TG, van der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <i>Science</i> 2020; 369(6504):843-850.
[0001]	Cal Y, Zhang J, Xiao T, et al. Distinct conformational states of SARS-CoV-2 spike protein. <i>Science</i> 2020;10.1126/science.abd4251
[0001]	Chen C-Y, Tran DM, Cavedon A, et al. Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles. <i>Mol Ther Nucleic Acids.</i> 2020;20:534-44.
[0001]	de Wit E, N van Doremalen, D Faizarano, et al. SARS and MERS: recent insights into emerging coronaviruses. <i>Nat Rev Microbiol</i> 2016;14(8):523-34
[0001]	Elia U, Ramishetti S, Dammes N, et al. Design of SARS-CoV-2 RBO mRNA Vaccine using Novel Ionizable Lipids. <i>bioRxiv</i> 2020.10.1101.2020.10.15.341537.
[0001]	Ennulat D, Magid-Slav M, Rehm S, et al. Diagnostic performance of traditional hepatobiliary biomarkers of drug-induced liver injury in the rat. <i>Toxicol Sci</i> 2010; 116(2):397-412.
[0001]	Fukuchi M, Saito R, Maki S, et al. Visualization of activity-regulated BDNF expression in the living mouse brain using non-invasive near-infrared bioluminescence imaging. <i>Mol Brain</i> 2020. 13(1):122.
[0001]	Hassett KJ, Benenato KE, Jacquinet E et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. <i>Mol Ther Nucleic acids</i> 2019;15:1-11.
[0001]	Henderson R, Edwards RJ, Mansouri K, et al. Controlling the SARS-CoV-2 spike glycoprotein conformation. <i>Nat Struct Mol Biol</i> 2020;(Jul);Online
[0001]	Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. <i>Cell</i> 2020. 181(2):271-280.e8
[0001]	Hülkötter RJ, de Haan CA, Bosch BJ. Coronavirus spike protein and tropism changes. <i>Adv Virus Res</i> 2016;96:25-57
[0001]	Hutloff A. Regulation of T follicular helper cells by ICOS. <i>Oncotarget</i> 2015;6(26)(Sep):21785-6.
[0001]	Jeon YH, Choi Y, Kang JH, et al. In vivo monitoring of DNA vaccine gene expression using firefly luciferase as a naked DNA. <i>Vaccine</i> 2006; 24(16):3067-62.
[0001]	Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. <i>Science and society. Trends Immunol</i> 2020; 41(5)(May):355-9
[0001]	Kariko K, Buckstein M, Ni H, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. <i>Immunity</i> 2005;2(Aug):165-75.
[0001]	Kaushal D, Foreman TW, Gautam US, et al. Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis. <i>Nat Commun</i> 2015; 6:8533.

[0001] Kaushal D, Foreman TW, Gautam US, et al. Mucosal vaccination with attenuated *Mycobacterium tuberculosis* induces strong central memory responses and protects against tuberculosis. *Nat Commun* 2015; 6:8533.

[0002] Ke Z, Oton J, Ou K, et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. *Nature* 2020; 10.1038/s41586-020-2665-2.

[0003] Kim JY, Ko JH, Kim Y, et al. Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. *J Korean Med Sci* 2020;35(7)(Feb):e86

[0004] Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature* 2020;584(7821):450-456.

[0005] Munster JV, Feldmann F, Williamson BN, et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. *Nature* 2020.(May):Accepted preview.

[0006] Murato AE, Fontes-Garfias CR, Ren P, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. *Nat Commun* 2020;11(1):4059.

[0007] Pallesen J, Wang N, Corbett KS, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. *Proc Natl Acad Sci USA* 2017;114(35):E7348-57

[0008] Pardi N, Hogan MJ, Pelc RS, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. *Nature* 2017;543(7644):248-51

[0009] Pardi N, Parkhouse K, Kirkpatrick E, et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. *Nat Commun* 2018;9(1):08:3361.

[0010] Sahin U, Kariko K, Tureci O. mRNA-based therapeutics - developing a new class of drugs. *Nat Rev Drug Discov* 2014;13(10):759-80

[0011] Sedic M, Senn J, Lynn A, et al. Safety evaluation of lipid nanoparticle-formulated modified mRNA in Sprague-Dawley rat and cynomolgus monkey. *Vet Pathol* 2018;55(2):341-54.

[0012] Sellers RS, Nelson K, Bindu Bennet B, et al. Scientific and Regulatory Policy Committee Points to Consider: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic Pathologists. *Toxicol Pathol* 2020;48(2):257.

[0013] Singh DK, SR Ganatra, B Singh et al. SARS-CoV-2 infection leads to acute infection with dynamic cellular and inflammatory flux in the lung that varies across nonhuman primate species. *bioRxiv* 10.1101/2020.06.05.136481 (2020).

[0014] Sliansky JE, Rattis FM, Boyd LF, et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. *Immunity* 2000; 13(4):529-38

[0015] Truong B, Allegri G, Liu X-B, et al. Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency. *Proc Natl Acad Sci USA*. 2019;116(42):21150-9.

[0016] US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Development and licensure of vaccines to prevent COVID-19. In: Guidance for industry. Rockville, MD: Food and Drug Administration; 2020.

[0017] World Health Organization. Annex 1. WHO guidelines on nonclinical evaluation of vaccines. In: World Health Organization. WHO technical report series, no. 927. Geneva, Switzerland: World Health Organization; 2005. p. 31-63

[0018] World Health Organization. Annex 2. Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines. In: WHO technical report series no. 987. Geneva, Switzerland: World Health Organization; 2014. p. 59-100

[0019] Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 2020;367(6483):1260-3

[0020] Wu Y, Wang F, Shen C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science* 2020; 368(6496):1274-8

[0021] Xie X, Muramoto A, Lokugamage KG, et al. An infectious cDNA clone of SARS-CoV-2. *Cell Host Microbe* 2020; 27(5):841-848.e3

[0022] Xie X, Muramoto A, Lokugamage KG, et al. An infectious cDNA clone of SARS-CoV-2. *Cell Host Microbe* 2020; 27(5):841-848.e3

[0023] Yong CY, Ong HK, Yeap SK, et al. Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus. *Front Microbiol* 2019;10:1781

[0024] Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science* 2020; 368(6491):630-3

[0025] Zakhartchouk AN, Sharon C, Satkunarajah M, et al. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. *Vaccine* 2007;25(1):136-43

[0026] Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. *Front Med* 2020(Apr):1-10

[0027] Zost Seth J, Gilchuk Pavo, Chen Rita E, et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein *Nature Medicine* 2020;26 9:1422-1427.

[0028] Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N Engl J Med* 2020;382(12)(03):1177-9.

Clinical Study Reports

## Section 5.3.1 - 125742/0/0

- ▶ 2 Common Technical Document Summaries
- ▶ 4 Nonclinical Study Reports
- ▲ 5 Clinical Study Reports
  - ▶ 5.2 Tabular Listing of all Clinical Studies
  - ▲ 5.3 Clinical Study Reports
    - ▲ 5.3.1 Reports of Biopharmaceutical Studies
      - ▲ 5.3.1.4 Reports of Bioanalytical and Analytical Methods for Human Studies
        - ▶ [0001] VR-MVR-10080 - Report on Method Validation of a Cepheid Xpert Xpress PCR Assay to Detect SARS-CoV-2
        - ▶ [0001] VR-MVR-10081 - Method Validation Report for the Elecsys Anti-SARS-CoV-2 Assay
        - ▶ [0001] VR-MVR-10083 - Validation Report for the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay
        - ▶ [0001] VR-MQR-10211 - Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for Quantitation of IgG Antibodies to SARS-CoV-2 S1 Protein in Human Sera
        - ▶ [0001] VR-MQR-10212 - Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for Quantitation of IgG Antibodies to SARS-CoV-2 RBD Protein in Human Sera
        - ▶ [0001] VR-MQR-10214 - Qualification of the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay
        - ▶ [0001] VR-TM-10293 - Single-plex Luminex Assay for Quantitation of IgG Antibodies to SARS-CoV-2 S1 Protein in Human Serum
        - ▶ [0001] VR-TM-10294 - Single-plex Luminex Assay for Quantitation of IgG Antibodies to SARS-CoV-2 RBD Protein in Human Serum
        - ▶ [0001] VR-TM-10298 - Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to SARS-CoV-2 in Test Serum
        - ▶ [0001] VR-TM-10304 - Test Method for the SARS CoV-2 Nucleocapsid (N) Antigen Detection Assay
        - ▶ [0001] VR-SOP-LC-11120 - Data Review Procedures for Direct Luminex Immunoassays in LIMS v6
        - ▶ [0001] SHI-SOP-10011 - Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to SARS-CoV-2 in Test Serum using Cytation 7 Image Reader
      - ▶ 5.3.5 Reports of Efficacy and Safety Studies
      - ▶ 5.3.6 Reports of Postmarketing Experience
    - ▶ 5.4 Literature References

- ▲ 5.3.1 Reports of Biopharmaceutical Studies
  - ▲ 5.3.1.4 Reports of Bioanalytical and Analytical Methods for Human Studies
    - ▲ [0001] VR-MVR-10080 - Report on Method Validation of a Cepheid Xpert Xpress PCR Assay to Detect SARS-CoV-2
      - ▲ Study Report Body Chapter
        - ▶ [0001] VR-MVR-10080
        - ▶ [0001] VR-MVR-10080-ATT01
        - ▶ [0001] VR-MVR-10080-ATT02
    - ▲ [0001] VR-MVR-10081 - Method Validation Report for the Elecsys Anti-SARS-CoV-2 Assay
      - ▲ Study Report Body Chapter
        - ▶ [0001] VR-MVR-10081
        - ▶ [0001] VR-MVR-10081-ATT01
    - ▲ [0001] VR-MVR-10083 - Validation Report for the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay
      - ▲ Study Report Body Chapter
        - ▶ [0001] VR-MVR-10083
        - ▶ [0001] VR-MVR-10083-ATT01
        - ▶ [0001] VR-MVR-10083-ATT02
        - ▶ [0001] VR-MVR-10083-ATT03
        - ▶ [0001] VR-MVR-10083-ATT04
    - ▲ [0001] VR-MQR-10211 - Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for Quantitation of IgG Antibodies to SARS-CoV-2 S1 Protein in Human Sera
      - ▲ Study Report Body Chapter

- ▲ [0001] VR-MQR-10211 - Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for Quantitation of IgG Antibodies to SARS-CoV-2 S1 Protein in Human Sera
  - ▲ Study Report Body Chapter
    - ▲ [0001] VR-MQR-10211
    - ▲ [0001] VR-MQR-10211-ATT01
- ▲ [0001] VR-MQR-10212 - Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for Quantitation of IgG Antibodies to SARS-CoV-2 RBD Protein in Human Sera
  - ▲ Study Report Body Chapter
    - ▲ [0001] VR-MQR-10212
    - ▲ [0001] VR-MQR-10212-ATT01
- ▲ [0001] VR-MQR-10214 - Qualification of the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay
  - ▲ Study Report Body Chapter
    - ▲ [0001] VR-MQR-10214
    - ▲ [0001] VR-MQR-10214-ATT01
    - ▲ [0001] VR-MQR-10214-ATT02
    - ▲ [0001] VR-MQR-10214-ATT03
- ▲ [0001] VR-TM-10293 - Single-plex Luminex Assay for Quantitation of IgG Antibodies to SARS-CoV-2 S1 Protein in Human Serum
  - ▲ Study Report Body Chapter
    - ▲ [0001] VR-TM-10293
- ▲ [0001] VR-TM-10294 - Single-plex Luminex Assay for Quantitation of IgG Antibodies to SARS-CoV-2 RBD Protein in Human Serum
  - ▲ Study Report Body Chapter
    - ▲ [0001] VR-TM-10294
- ▲ [0001] VR-TM-10298 - Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to SARS-CoV-2 in Test Serum
  - ▲ Study Report Body Chapter

- ▲ [0001] VR-TM-10298 - Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to SARS-CoV-2 in Test Serum
  - ▲ Study Report Body Chapter
    - ▲ [0001] VR-TM-10298
- ▲ [0001] VR-TM-10304 - Test Method for the SARS CoV-2 Nucleocapsid (N) Antigen Detection Assay
  - ▲ Study Report Body Chapter
    - ▲ [0001] VR-TM-10304
- ▲ [0001] VR-SOP-LC-11120 - Data Review Procedures for Direct Luminex Immunoassays in LIMS v6
  - ▲ Study Report Body Chapter
    - ▲ [0001] VR-SOP-LC-11120
- ▲ [0001] SHI-SOP-10011 - Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to SARS-CoV-2 in Test Serum using Cytation 7 Image Reader
  - ▲ Study Report Body Chapter
    - ▲ [0001] SHI-SOP-10011
- ▶ 5.3.5 Reports of Efficacy and Safety Studies
- ▶ 5.3.6 Reports of Postmarketing Experience
- ▶ 5.4 Literature References

\*\*\*FOR OFFICIAL USE ONLY\*\*\*

## Exclude Inspection Related

Order: FDA/Apl, Then Date Ascending

\*\*\*THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION\*\*\*

STN: L 125742/0

Applicant: BioNTech Manufacturing GmbH #2229

Product: COVID-19 Vaccine, mRNA

Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.

Date	Elec	Post	Description	FDA Recd Date	Login ID
13-MAY-2021	Y		Letter. Acknowledgement Letter - Rolling Review ( DICKERSON, DAVID )		
18-MAY-2021	Y		Telecon. Information Request - IR RE datasets. ( SMITH, MICHAEL )		
20-MAY-2021	Y		Telecon. Information Request - Four facility questions from DMPQ and a request for a t-con on 5/25/21 or 5/26/21 to discuss production schedules and the shutdown activities planned for the Puurs, Belgium site. ( SMITH, MICHAEL )		
03-JUN-2021	Y		Meeting Summary. First Committee Meeting - First Committee Meeting Summary ( NAIK, RAMACHANDRA )		
08-JUN-2021	Y		Telecon. Information Request - Three clinical questions. ( SMITH, MICHAEL )		
09-JUN-2021	Y		Telecon. Information Request - IR for PREA dates for deferred pediatric studies. ( SMITH, MICHAEL )		
17-JUN-2021	Y		Memo. Other - Permission to release License number to applicant prior to approval. ( JONECKIS, CHRISTOPHER )		
25-JUN-2021	Y		Telecon. Information Request - IR from DBSQC regarding the lot release protocol (LRP) template and samples & reagents. ( SMITH, MICHAEL )		
25-JUN-2021	Y		Telecon. Information Request - IR regarding the document titled "bnt162-01-interim3-report-body". ( SMITH, MICHAEL )		
29-JUN-2021	Y		Meeting Summary. Filing Meeting Summary - Summary of the June 29, 2021 Filing Meeting. The BLA is fileable. ( NAIK, RAMACHANDRA )		
29-JUN-2021	Y		Telecon. Information Request - Clinical IR regarding Study C4591001. ( SMITH, MICHAEL )		
01-JUL-2021	Y		Memo. Filing Checklist/RPM - RPM Filing Checklist - the application is fileable. ( GOTTSCHALK, LAURA )		
02-JUL-2021	Y		Memo. Committee Memo/APLB - PNR COMIRNATY: ACCEPTABLE ( ELEKWACHI, OLUCHI )		
02-JUL-2021	Y		Telecon. Advice - Advice: Pfizer's assumption as outlined in Elisa Harkins June 29, 2021 e-mail RE the bnt162-01-interim3-report-body are correct. ( SMITH, MICHAEL )		
02-JUL-2021	Y		Telecon. Information Request - Comments regarding CMC information and categorical exclusion for an environment analysis ( NAIK, RAMACHANDRA )		
06-JUL-2021	Y		Telecon. PNR Acceptance / Advice - The Applicant was informed that their proprietary name "COMIRNATY" is acceptable. ( SMITH, MICHAEL )		
06-JUL-2021	Y		Telecon. Information Request - Clinical IR RE the document titled "c4591001-interim-mth6-report-body.pdf." ( SMITH, MICHAEL )		
09-JUL-2021	Y		Telecon. Information Request - IR RE the validation of the RNA Integrity by capillary gel electrophoresis (CGE) method. ( SMITH, MICHAEL )		
13-JUL-2021	Y		Telecon. Information Request - OBE IR RE adding myocarditis and pericarditis to the PVP. ( SMITH, MICHAEL )		
13-JUL-2021	Y		Telecon. Information Request - DVP IR regarding exception or alternative to the requirement that products in multiple-dose vials include a preservative ( NAIK, RAMACHANDRA )		
15-JUL-2021	Y		Letter. Filing Notification Letter / No Deficiencies Identified - Filing Notification No Deficiencies Identified ( SMITH, MICHAEL )		
15-JUL-2021	Y		Telecon. Information Request - IR RE Study C4591007; please provide updated goal dates for final protocol submission. ( SMITH, MICHAEL )		
15-JUL-2021	Y		Meeting Summary. Committee Meeting Summary - Summary of the July 15, 2021 Monthly Committee Meeting. ( GOTTSCHALK, LAURA )		
15-JUL-2021	Y		Telecon. Information Request - F/U IR RE updated PVP by 7/29/21. ( SMITH, MICHAEL )		
16-JUL-2021	Y		Telecon. Information Request - DBSQC IR regarding lot release protocol template and drug substance handling instructions. ( GOTTSCHALK, LAURA )		

\*\*\*FOR OFFICIAL USE ONLY\*\*\*

## Exclude Inspection Related

Order: FDA/Apl, Then Date Ascending

\*\*\*THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION\*\*\*

STN: L 125742/0

Applicant: BioNTech Manufacturing GmbH #2229

Product: COVID-19 Vaccine, mRNA

Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.

Date	Elec	Post	Description	FDA Recd Date	Login ID
16-JUL-2021	Y		Telecon. Information Request - DBSQC IR regarding (b) (4) and (b) (4) test methods ( GOTTSCHALK, LAURA )		
19-JUL-2021	Y		Telecon. Advice - US license number 2229 was provided to the applicant prior to approval in response to the request included in the cover letter of the first roll of their BLA on May 6, 2021. ( NAIK, RAMACHANDRA )		
20-JUL-2021	Y		Memo. Review - CDISC validation results and discussion ( BALDWIN, BRENDA )		
20-JUL-2021	Y		Telecon. Information Request - Clinical IR for a revised pediatric plan to include study C4591007 for subject 6 months to 11 years of age and proposal of another study to enroll infants <6 months of age. ( NAIK, RAMACHANDRA )		
22-JUL-2021	Y		Telecon. Information Request - Clinical and stats IR regarding shell tables to include safety and efficacy data from study C4591001 and other clinical comments ( GOTTSCHALK, LAURA )		
26-JUL-2021	Y		Telecon. Information Request - Clinical IR regarding the disposition of participants in safety populations who experienced pregnancy. ( GOTTSCHALK, LAURA )		
26-JUL-2021	Y		Telecon. Information Request - DMPQ IR regarding manufacturing and equipment ( GOTTSCHALK, LAURA )		
27-JUL-2021	Y		Telecon. Information Request - Clinical IR RE vaccine effectiveness ( SMITH, MICHAEL )		
27-JUL-2021	Y		Telecon. Information Request - Third clinical IR RE vaccine effectiveness. ( SMITH, MICHAEL )		
28-JUL-2021	Y		Telecon. Labeling Target Closure / Labeling via FAX/e-mail - First set of labeling comments regarding the PI ( NAIK, RAMACHANDRA )		
28-JUL-2021	Y		Telecon. Information Request - OBE IR regarding postmarketing safety study(ies) ( NAIK, RAMACHANDRA )		
29-JUL-2021	Y		Telecon. Information Request - Clinical IR regarding safety analysis for two age groups ( GOTTSCHALK, LAURA )		
02-AUG-2021	Y		Telecon. Information Request - Questions regarding the Validation Report VR-MVR-10077 ( SMITH, MICHAEL )		
02-AUG-2021	Y		Telecon. Information Request - Five questions regarding validation of assay methods and lot release. ( SMITH, MICHAEL )		
03-AUG-2021	Y		Telecon. Information Request - Six CMC-related questions. ( SMITH, MICHAEL )		
03-AUG-2021	Y		Telecon. Information Request - Two clinical/stats questions regarding July 26, 2021, submission and SAS programs. ( SMITH, MICHAEL )		
04-AUG-2021	Y		Telecon. Information Request - Two questions regarding the potency assay for determination of (b) (4) by (b) (4). ( SMITH, MICHAEL )		
04-AUG-2021	Y		Telecon. Information Request - F/U IR RE the LRP that was submitted to BLA 125742/0.14 on July 20, 2021. ( SMITH, MICHAEL )		
04-AUG-2021	Y		Telecon. Information Request - Secondary e-mail with attachment RE 8/4/21 F/U LRP comments. ( SMITH, MICHAEL )		
05-AUG-2021	Y		Telecon. Advice - Informed the applicant regarding the PROPER NAME for their product in this BLA. ( GOTTSCHALK, LAURA )		
05-AUG-2021	Y		Telecon. Information Request - 11 facility questions. ( SMITH, MICHAEL )		
05-AUG-2021	Y		Telecon. Information Request - Four questions regarding the diluent. ( SMITH, MICHAEL )		
05-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - 2nd round of PI labeling comments. ( SMITH, MICHAEL )		
06-AUG-2021	Y		Letter. UNII Code Notification - Unique Ingredient Identifier (UNII) Code Assignment ( SMITH, MICHAEL )		
06-AUG-2021	Y		Memo. Committee Memo/APLB - APLB BLA LR ( ELEKWACHI, OLUCHI )		

\*\*\*FOR OFFICIAL USE ONLY\*\*\*

## Exclude Inspection Related

Order: FDA/Apl, Then Date Ascending

\*\*\*THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION\*\*\*

STN: L 125742/0

Applicant: BioNTech Manufacturing GmbH #2229

Product: COVID-19 Vaccine, mRNA

Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.

Date	Elec	Post	Description	FDA Recd Date	Login ID
06-AUG-2021	Y	Y	Memo. Review - OBE/DE Pharmacovigilance Review ( THOMPSON, DEBORAH )		
06-AUG-2021	Y		Telecon. Information Request - IR RE two DP documents. ( SMITH, MICHAEL )		
06-AUG-2021	Y		Telecon. Information Request - Three DBSQC questions RE measurement of (b) (4) using the (b) (4) procedures. ( SMITH, MICHAEL )		
09-AUG-2021	Y		Telecon. Advice - Advice RE submitting samples, LRP and distribution of EUA and BLA labeled product after COMIRNATY is licensed. ( SMITH, MICHAEL )		
09-AUG-2021	Y		Telecon. Information Request - Clinical IR RE sequencing data. ( SMITH, MICHAEL )		
09-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - Comments on the Carton and Container labels ( SMITH, MICHAEL )		
10-AUG-2021	Y		Telecon. Information Request - Second OBE IR regarding safety-related postmarketing studies. ( NAIK, RAMACHANDRA )		
10-AUG-2021	Y		Telecon. Information Request - One testing related question from DBSQC. ( SMITH, MICHAEL )		
11-AUG-2021	Y		Telecon. Information Request - One question from DMPQ regarding the diluent that is to be provided with the vaccine. ( SMITH, MICHAEL )		
11-AUG-2021	Y		Telecon. Other - This teleconference between CBER and Pfizer was to seek clarity on availability of EUA and BLA products and plans for distribution after licensure of COMIRNATY. ( SMITH, MICHAEL )		
12-AUG-2021	Y		Memo. Committee Memo/Require Pre-Approval Inspection ( CHEUNG, ANISSA )		
12-AUG-2021	Y		Telecon. Other - Teleconference between CBER and Pfizer to receive clarification on how EUA lots and BLA lots will be indentified. ( NAIK, RAMACHANDRA )		
13-AUG-2021	Y	Y	Memo. Committee Memo/BIMO - BIMO Discipline Review Memo ( CHUN, HAECIN )		
13-AUG-2021	Y		Memo. Request For Compliance Check - Request for Compliance check. ( ZUBKOVA, IRYNA )		
13-AUG-2021	Y		Telecon. Information Request - Three clinical questions. ( SMITH, MICHAEL )		
13-AUG-2021	Y		Telecon. Information Request - DBQSC IR LRP and testing. ( SMITH, MICHAEL )		
13-AUG-2021	Y		Telecon. Information Request - 7 facility questions from the DMPQ team. ( SMITH, MICHAEL )		
13-AUG-2021	Y		Telecon. Information Request - A clinical IR was sent on 13AUG21 and Pfizer had a clarification question. This IR t-con was in response to the F/U clarification question. ( SMITH, MICHAEL )		
13-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - 3rd set of PI labeling comments. ( SMITH, MICHAEL )		
13-AUG-2021	Y		Telecon. Information Request - One clinical question. ( SMITH, MICHAEL )		
13-AUG-2021	Y		Telecon. Information Request - IR RE PMR's and PMC's. ( SMITH, MICHAEL )		
16-AUG-2021	Y		Telecon. Information Request - DMPQ IR RE (b) (4) (b) (4) . ( SMITH, MICHAEL )		
16-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - Second set of comments and questions on the carton and container labels. ( SMITH, MICHAEL )		
16-AUG-2021	Y		Telecon. Information Request - Teleconference regarding measurement of (b) (4) . Pfizer commits to implement (b) (4) testing method on (b) (4) . ( SMITH, MICHAEL )		

\*\*\*FOR OFFICIAL USE ONLY\*\*\*

## Exclude Inspection Related

Order: FDA/Apl, Then Date Ascending

\*\*\*THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION\*\*\*

STN: L 125742/0

Applicant: BioNTech Manufacturing GmbH #2229

Product: COVID-19 Vaccine, mRNA

Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.

Date	Elec	Post	Description	FDA Recd Date	Login ID
16-AUG-2021	Y		Telecon. Information Request - Please submit this same CMC stability information that was submitted to EUA 27034.260 to your BLA STN 125742.0 so that we can consider a 9-month shelf-life for the licensed product. ( NAIK, RAMACHANDRA )		
17-AUG-2021	Y		Memo. Lot Release Clearance Memo / Lot Release Clearance Request - Lot Release Clearance Request and Lot Release Clearance Memo. ( BESHIR, LEYLA )		
17-AUG-2021	Y		Memo. Other; Non-proprietary name does not include a suffix - Justification memo regarding approving non-proprietary name without a suffix ( GRUBER, MARION )		
17-AUG-2021	Y		Telecon. Other - The purpose of the teleconference between DMPQ and Pfizer was to discuss items 2b, 2c, 6 and 9c from the FDA form 483 for the Andover site. ( SMITH, MICHAEL )		
17-AUG-2021	Y		Telecon. Information Request - Two questions from Xiao Wang regarding drug substance. ( SMITH, MICHAEL )		
17-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - 4th set of PI labeling comments. ( SMITH, MICHAEL )		
17-AUG-2021	Y		Telecon. Information Request - Follow up IR RE PMR & PMC's commitments that were received in amendment 51 dated August 16, 2021. ( NAIK, RAMACHANDRA )		
17-AUG-2021	Y		Telecon. Information Request - DVP IR regarding two questions on shelf life and date of manufacture. ( SMITH, MICHAEL )		
18-AUG-2021	Y		Memo. Committee Memo/Review - DBSQC LRP template review memo ( ANDERSON, MARIE )		
18-AUG-2021	Y	Y	Memo. Committee Memo/Statistical Non-Clinical - Statistical review memo for non-clinical data ( TANG, XINYU )		
18-AUG-2021	Y		Telecon. Advice - Pfizer e-mailed clarification questions on August 18, 2021, to DVP's two DS questions dated August 17, 2021. This e-mail was guidance in response to their clarification questions. ( SMITH, MICHAEL )		
18-AUG-2021	Y		Telecon. Information Request - Two DBSQC questions on amendments 54 and 50 RE (b) (4) testing and specific parameters/instructions for (b) (4) (b) (4) test method. ( SMITH, MICHAEL )		
18-AUG-2021	Y		Telecon. Information Request - DVP follow-up response to Pfizer August 18, 2021, clarification questions regarding DVP's August 17, 2021, IR on shelf life and date of manufacture. ( SMITH, MICHAEL )		
18-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - 5th set of PI labeling comments. ( SMITH, MICHAEL )		
18-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - 3rd set of comments on the carton and container labels. ( GOTTSCHALK, LAURA )		
18-AUG-2021	Y		Telecon. Information Request - Identification of BLA-compliant lots and Letter to HCP. ( NAIK, RAMACHANDRA )		
19-AUG-2021	Y	Y	Memo. Committee Memo/Statistical Clinical - Statistical memo for clinical efficacy data ( HUANG, LEI )		
19-AUG-2021	Y	Y	Memo. Committee Memo/Statistical Clinical - Statistical review for safety data. ( YANG, YE )		
19-AUG-2021	Y		Memo. Compliance Check Acceptable - Compliance check is acceptable. ( DECIERO, DANIEL )		
19-AUG-2021	Y		Telecon. Information Request - IR RE PMR's and PMC's that were listed in amendment 51. ( SMITH, MICHAEL )		
19-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - 6th set of PI labeling comments. ( GOTTSCHALK, LAURA )		
19-AUG-2021	Y		Telecon. Information Request - IR RE PMC Study Completion Date and Final Report Submission date for PMC Study C4591014. ( SMITH, MICHAEL )		
20-AUG-2021	Y		Memo. Committee Memo/Labeling - Review Memo: Containers, Cartons, Sticker, Stamp ( STEWART, DAPHNE )		

\*\*\*FOR OFFICIAL USE ONLY\*\*\*

## Exclude Inspection Related

Order: FDA/Apl, Then Date Ascending

\*\*\*THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION\*\*\*

STN: L 125742/0

Applicant: BioNTech Manufacturing GmbH #2229

Product: COVID-19 Vaccine, mRNA

Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.

Date	Elec	Post	Description	FDA Recd Date	Login ID
20-AUG-2021	Y		Memo. Other - CONFIDENTIAL - DO NOT POST TO THE WEB CBER Laboratory Quality Product Testing Plan ( ANDERSON, MARIE )		
20-AUG-2021	Y	Y	Memo. Review - Pharmacovigilance Plan Review; Addendum Memorandum ( WELSH, KERRY )		
20-AUG-2021	Y		Memo. Test Results - In-support (b) (4) Test Results ( KONG, HYESUK )		
20-AUG-2021	Y		Memo. Test Results - Test memo for (b) (4) ( WANG, HSIAOLING )		
20-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - 7th set of PI comments and shell table. ( GOTTSCHALK, LAURA )		
20-AUG-2021	Y		Telecon. Information Request / Advice - Lot Numbers for the COVID Launch Lots ( NAIK, RAMACHANDRA )		
20-AUG-2021	Y		Telecon. Information Request - CBER comments regarding label for identification of BLA lots and Dear HCP Letter ( NAIK, RAMACHANDRA )		
20-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - Comment regarding vial label to include the name of the diluent on vial labels. ( GOTTSCHALK, LAURA )		
21-AUG-2021	Y	Y	Memo. Committee Memo/CMC - CMC Product Review Memo ( WANG, XIAO )		
21-AUG-2021	Y	Y	Memo. Committee Memo/CMC - DBSQC Analytical Review Memo ( YITBAREK, EMNET )		
21-AUG-2021	Y		Telecon. Information Request - IR RE request to resubmit all PMR's and PMC's and a commitment to conduct them in the timeframe noted in an amendment to the BLA. Also, revised study completion date for study C4591007. ( SMITH, MICHAEL )		
21-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - 8th set of PI labeling comments ( GOTTSCHALK, LAURA )		
21-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - The Applicant was notified that the Carton and Container labels submitted in Amendment 63 dated August 19, 2021, are considered the Final Draft Labels for approval. ( GOTTSCHALK, LAURA )		
21-AUG-2021	Y		Telecon. Information Request - CBER comments regarding label for identification of BLA lots and Dear HCP Letter. ( NAIK, RAMACHANDRA )		
21-AUG-2021	Y		Telecon. Advice - The Applicant was notified that there are no additional comments on the Dear HCP letter submitted in Amendment 73 submitted August 21, 2021. ( NAIK, RAMACHANDRA )		
22-AUG-2021	Y	Y	Memo. Committee Memo/Postmarketing Safety Epidemiological - OBE Real World Evidence Memo ( LU, YUN )		
22-AUG-2021	Y	Y	Memo. Committee Memo/Review - DMPQ Review Memo - Recommend approval ( JONES, KATHLEEN )		
22-AUG-2021	Y	Y	Memo. Other - Employee/Officer List Memo ( GOTTSCHALK, LAURA )		
22-AUG-2021	Y		Telecon. Labeling via FAX/e-mail - The Applicant was notified that the Package Insert submitted in Amendment 74 dated August 21, 2021, is considered the Final Draft Label for approval ( GOTTSCHALK, LAURA )		
23-AUG-2021	Y	Y	Letter. Approval - BLA Approval Letter ( SMITH, MICHAEL )		
23-AUG-2021	Y	Y	Memo. Committee Memo/SBRA - SBRA - Summary Basis for Regulatory Action ( NAIK, RAMACHANDRA )		
23-AUG-2021	Y	Y	Memo. Committee Memo/Toxicology - Committee Memo/Toxicology ( AL-HUMADI, NABIL )		
23-AUG-2021	Y		Memo. Other - OCOD Transmittal Memo for web posting ( SMITH, MICHAEL )		
23-AUG-2021	Y	Y	Memo. Review - OBE Sentinel Sufficiency Assessment ( OBIDI, JOYCE )		

\*\*\*FOR OFFICIAL USE ONLY\*\*\*

## Exclude Inspection Related

Order: FDA/Apl, Then Date Ascending

\*\*\*THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION\*\*\*

STN: L 125742/0

Applicant: BioNTech Manufacturing GmbH #2229

Product: COVID-19 Vaccine, mRNA

Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.

Date	Elec	Post	Description	FDA Recd Date	Login ID
30-AUG-2021	Y		Telecon. Other - Amendment 125742.0.41 was reviewed in the DBSQC memo dated 08/20/2021. Pfizer's responses were acceptable. ( WANG, HSIAOLING )		
30-AUG-2021	Y		Telecon. Other - Amendment 125742.0.60 was reviewed in the Andover 483 response memo. Pfizer's responses were acceptable. ( JONES, KATHLEEN )		
01-SEP-2021	Y		Memo. Committee Memo/Labeling - RPM Labeling Review Memo ( GOTTSCHALK, LAURA )		
02-SEP-2021	Y	Y	Memo. Committee Memo/Clinical Review - Committee Memo/Clinical Review. Ann Schwartz and Lucia Lee contributed to this review memo. ( WOLLERSHEIM, SUSAN )		
13-SEP-2021	Y	Y	Memo. Committee Memo/Review / Benefit-Risk assessment - Benefit-Risk assessment review memo; Patrick Funk, Ph.D., and Osman N. Yogurtcu, Ph.D., also contributed to the review memo. ( YANG, HONG )		
13-SEP-2021	Y		Memo. Committee Memo/Review - Documentation review memo. ( SMITH, MICHAEL )		
30-SEP-2021	Y	Y	Memo. Revised Post Lockdown / Committee Memo/Toxicology - Revised Post Lockdown/ Committee Memo/Toxicology/23-Aug-2021 ( AL-HUMADI, NABIL )		
08-NOV-2021	Y	Y	Memo. Revised Post Lockdown / Committee Memo/SBRA - Table 2 header and value for water in the table were changed. ( NAIK, RAMACHANDRA )		
06-MAY-2021	Y		Original Application. For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.	06-MAY-2021	1067058
18-MAY-2021	Y		Amendment # 1. Second and final rolling piece to start the review clock.	18-MAY-2021	1086158
19-MAY-2021	Y		Amendment # 2. Request for Proprietary Name Review	19-MAY-2021	1087747
19-MAY-2021	Y		Amendment # 3. Response to May 18, 2021, clinical IR RE three dataset questions.	19-MAY-2021	1088844
24-MAY-2021	Y		Amendment # 4. Response to DMPQ's May 20, 2021, IR RE four facilities questions and a request for a t-con on 5/25/21 or 5/26/21 to discuss production schedules and the shutdown activities planned for the Puurs, Belgium site.	24-MAY-2021	1094917
07-JUN-2021	Y		Amendment # 5. COVID-19 case strain sequencing data.	07-JUN-2021	1119355
16-JUN-2021	Y		Amendment # 6. Response to June 8, 2021, clinical IR on three clinical questions regarding datasets and the PI.	16-JUN-2021	1137474
17-JUN-2021	Y		Amendment # 7. Response to June 9, 2021, clinical IR requesting dates for PREA deferred studies.	17-JUN-2021	1139420
02-JUL-2021	Y		Amendment # 8. Response to June 29, 2021, clinical IR RE latest date of randomization for participants included in the reactogenicity subset for Study C4591001.	02-JUL-2021	1168170
02-JUL-2021	Y		Amendment # 9. Response to June 25, 2021, clinical IR regarding IR regarding the document titled ;bnt162-01-interim3-report-body;	02-JUL-2021	1168177
09-JUL-2021	Y		Amendment # 10. Response to DBSQC's June 25, 2021, IR regarding the lot release protocol (LRP) template and samples & reagents.	09-JUL-2021	1183932
15-JUL-2021	Y		Amendment # 11. Response to DVP's July 13, 2021, IR regarding exception or alternative to the requirement that products in multiple-dose vials include a preservative.	15-JUL-2021	1199647
16-JUL-2021	Y		Amendment # 12. Response to July 6, 2021, clinical IR regarding IR regarding the document titled ;c4591001-interim-mth6-report-body.pdf.;	16-JUL-2021	1201833
19-JUL-2021	Y		Amendment # 13. The applicant waives their rights to the mid- and late-cycle review meetings for BLA 125742.	19-JUL-2021	1204967
20-JUL-2021	Y		Amendment # 14.	20-JUL-2021	1207929

\*\*\*FOR OFFICIAL USE ONLY\*\*\*

## Exclude Inspection Related

Order: FDA/Apl, Then Date Ascending

\*\*\*THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION\*\*\*

STN: L 125742/0

Applicant: BioNTech Manufacturing GmbH #2229

Product: COVID-19 Vaccine, mRNA

Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.

Date	Elec	Post	Description	FDA Recd Date	Login ID
23-JUL-2021	Y		Amendment # 15. Response to July 15, 2021, Clinical IR RE study C4591007 to provide updated goal dates for final protocol submission and July 20, 2021 follow-up Clinical IR for a revised pediatric plan to include study C4591007 for subject 6 months to 11 years of age and proposal of another study to enroll infants <6 months of age.	23-JUL-2021	1217479
23-JUL-2021	Y		Amendment # 16. Response to July 9, 2021 IR RE the validation of the RNA Integrity by capillary gel electrophoresis method.	23-JUL-2021	1217492
26-JUL-2021	Y		Amendment # 17. Responses to questions 3-5 of July 22, 2021 clinical and stats IR regarding shell tables to include safety and efficacy data from study C4591001 and other clinical comments.	26-JUL-2021	1221258
28-JUL-2021	Y		Amendment # 18. Responses to questions 1-2 of July 22, 2021 clinical and stats IR regarding shell tables to include safety and efficacy data from study C4591001 and other clinical comments.	28-JUL-2021	1227088
28-JUL-2021	Y		Amendment # 19. Response to July 2, 2021 DVP IR regarding 18 question on product related issues and categorical exclusion for an environmental assessment.	28-JUL-2021	1227383
30-JUL-2021	Y		Amendment # 22. Response to July 27, 2021 third Clinical IR RE vaccine effectiveness.	30-JUL-2021	1233501
30-JUL-2021	Y		Amendment # 24. Response to July 26, 2021 DMPQ IR regarding manufacturing and equipment.	30-JUL-2021	1236249
02-AUG-2021	Y		Amendment # 25. Response to the observations contained in the FDA form 483 that was issued for the pre-approval inspection of the Pfizer Andover facility.	02-AUG-2021	1236634
02-AUG-2021	Y		Amendment # 26. Response to July 29, 2021 clinical IR regarding safety analysis for two age groups.	02-AUG-2021	1237210
02-AUG-2021	Y		Amendment # 27. Response to 7/28/2021 first set of labeling comments regarding the PI.	02-AUG-2021	1237211
02-AUG-2021	Y		Amendment # 28. Response to comment 5b of July 22, 2021 clinical- statistical IR.	02-AUG-2021	1237740
03-AUG-2021	Y		Amendment # 29. Follow-up response (remaining supporting documents to response 10) to July 26, 2021 DMPQ IR regarding manufacturing and equipment.	03-AUG-2021	1241021
03-AUG-2021	Y		Amendment # 30. Response to OBE's July 28, 2021 comments regarding post marketing observational safety study(ies) to assess myocarditis/pericarditis following administration of COMIRNATY as well as providing plans to characterize subclinical cases of myocarditis.	03-AUG-2021	1241533
05-AUG-2021	Y		Amendment # 31. Response to DVP and OBE Questions regarding the Validation Report VR-MVR-10077.	05-AUG-2021	1247205
05-AUG-2021	Y		Amendment # 32. Response to clinical and stats IR's from July 22nd and August 4th regarding shell tables and two additional clinical/stats questions regarding July 26, 2021, submission and SAS program.	05-AUG-2021	1247821
06-AUG-2021	Y		Amendment # 33. Responses to DVP's six CMC-related questions from August 3, 2021.	06-AUG-2021	1249468
06-AUG-2021	Y		Amendment # 34. Responses to August 4, 2021, IR RE two questions regarding the potency assay for determination of (b) (4) by (b) (4).	06-AUG-2021	1249503
09-AUG-2021	Y		Amendment # 35. Response to DBSQC and Xiao Wang's August 2, 2021, questions regarding validation of assay methods and lot release.	09-AUG-2021	1252956
09-AUG-2021	Y		Amendment # 36. Response to four questions regarding the diluent dated August 5, 2021.	09-AUG-2021	1252957
09-AUG-2021	Y		Amendment # 37. Response to July 22nd Clinical and stats IR regarding shell tables to include safety and efficacy data from study C4591001.	09-AUG-2021	1252966
09-AUG-2021	Y		Amendment # 38. Revised PI labeling in response to August 5, 2021, second round of labeling comments.	09-AUG-2021	1253712
10-AUG-2021	Y		Amendment # 39. Response to Xiao Wang's August 6, 2021, questions regarding two drug product (DP) documents.	10-AUG-2021	1258976

\*\*\*FOR OFFICIAL USE ONLY\*\*\*

## Exclude Inspection Related

Order: FDA/Apl, Then Date Ascending

\*\*\*THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION\*\*\*

STN: L 125742/0

Applicant: BioNTech Manufacturing GmbH #2229

Product: COVID-19 Vaccine, mRNA

Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.

Date	Elec	Post	Description	FDA Recd Date	Login ID
11-AUG-2021	Y		Amendment # 40. Response to August 4, 2021, F/U IR RE the LRP that was submitted to BLA 125742/0.14 on July 20, 2021.	11-AUG-2021	1271302
11-AUG-2021	Y		Amendment # 41. Response to one testing related question from DBSQC on August 10, 2021.	11-AUG-2021	1271303
11-AUG-2021	Y		Amendment # 42. Response to August 10, 2021, second OBE IR regarding safety-related postmarketing studies.	11-AUG-2021	1271308
11-AUG-2021	Y		Amendment # 43. Responses to DMPQ <sub>ç</sub> s August 5, 2021 11 facilities questions.	11-AUG-2021	1273180
11-AUG-2021	Y		Amendment # 44. This amendment was skipped by the Applicant.	11-AUG-2021	1273179
12-AUG-2021	Y		Amendment # 45. Response to August 9, 2021, clinical IR RE sequencing data.	12-AUG-2021	1278583
13-AUG-2021	Y		Amendment # 46. Response to August 9, 2021 IR RE Carton and Container labeling comments.	13-AUG-2021	1284081
13-AUG-2021	Y		Amendment # 47. Response to DMPQ <sub>ç</sub> s August 11, 2021, diluent IR and amended response to Theresa Finn <sub>ç</sub> s August 5, 2021, IR regarding diluent.	13-AUG-2021	1284082
13-AUG-2021	Y		Amendment # 48. Response to DBSQC <sub>ç</sub> s August 6, 2021, three questions RE measurement of (b) (4) using (b) (4) (b) (4) procedures.	13-AUG-2021	1284088
16-AUG-2021	Y		Amendment # 49. Response to 3rd set of PI labeling comments that were sent on August 13, 2021.	16-AUG-2021	1310580
16-AUG-2021	Y		Amendment # 50. Response to DBSQC <sub>ç</sub> s August 13, 2021, IR RE LRP and testing.	16-AUG-2021	1310586
16-AUG-2021	Y		Amendment # 51. Response to August 13, 2021, IR RE Safety-related Postmarketing Requirement/Postmarketing Commitment studies.	16-AUG-2021	1310587
16-AUG-2021	Y		Amendment # 52. Response to three clinical questions dated August 13, 2021, plus an additional clinical question dated August 13, 2021 (four total clinical questions dated August 13, 2021).	16-AUG-2021	1310589
17-AUG-2021	Y		Amendment # 53. Response to August 16, 2021 IR RE Carton and Container labeling comments.	17-AUG-2021	1318912
17-AUG-2021	Y		Amendment # 54. Response to follow-up to August 13, 2021, (b) (4) IR and August 16, 2021, teleconference on this subject containing a commitment to implement (b) (4) method on (b) (4).	17-AUG-2021	1320863
17-AUG-2021	Y		Amendment # 55. Response to Xiao Wang <sub>ç</sub> s August 16, 2021, IR to please submit the same CMC stability information that was submitted to EUA 27034.260 to your BLA STN 125742 .0.	17-AUG-2021	1320989
17-AUG-2021	Y		Amendment # 56. Response to DMPQ <sub>ç</sub> s August 16, 2021, IR to (b) (4) (b) (4).	17-AUG-2021	1321046
17-AUG-2021	Y		Amendment # 57. Response to DMPQ <sub>ç</sub> s 7 facility questions dated August 13, 2021.	17-AUG-2021	1321051
18-AUG-2021	Y		Amendment # 58. Response to August 17, 2021, 4th set of PI labeling comments.	18-AUG-2021	1329921
18-AUG-2021	Y		Amendment # 59. Response to August 17, 2021, follow up IR RE PMR & PMC's commitments that were received in amendment 51 dated August 16, 2021.	18-AUG-2021	1329922
18-AUG-2021	Y		Amendment # 60. Updated response to FDA form 483 for the Andover site based off of teleconference with CBER on August 17, 2021.	18-AUG-2021	1331100
19-AUG-2021	Y		Amendment # 61. Responses to DVP <sub>ç</sub> s August 17, 2021, two questions regarding shelf life and date of manufacture.	19-AUG-2021	1337760
19-AUG-2021	Y		Amendment # 62. Responses to DVP <sub>ç</sub> s August 17, 2021, two questions regarding the drug substance.	19-AUG-2021	1337762
19-AUG-2021	Y		Amendment # 63. Responses to the third set of comments and questions on the carton and container labels.	19-AUG-2021	1338337
19-AUG-2021	Y		Amendment # 64. Response to August 18, 2021, IR RE Identification of BLA-compliant lots and Letter to HCP.	19-AUG-2021	1338338
19-AUG-2021	Y		Amendment # 65. Responses to DBSQC <sub>ç</sub> s August 18, 2021, IR.	19-AUG-2021	1338341

\*\*\*FOR OFFICIAL USE ONLY\*\*\*

## Exclude Inspection Related

Order: FDA/Apl, Then Date Ascending

\*\*\*THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION\*\*\*

STN: L 125742/0

Applicant: BioNTech Manufacturing GmbH #2229

Product: COVID-19 Vaccine, mRNA

Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.

Date	Elec	Post	Description	FDA Recd Date	Login ID
19-AUG-2021	Y		Amendment # 66. Response to August 18, 2021, 5th set of PI labeling comments.	19-AUG-2021	1338872
19-AUG-2021	Y		Amendment # 67. Response August 19, 2021, IR RE PMR <sub>ç</sub> s and PMC <sub>ç</sub> s that were submitted in amendment 51.	19-AUG-2021	1339769
20-AUG-2021	Y		Amendment # 68. Response to August 19, 2021, 6th set of PI labeling comments.	20-AUG-2021	1341754
20-AUG-2021	Y		Amendment # 69. Additional Response to August 19, 2021, IR RE PMR <sub>ç</sub> s and PMC <sub>ç</sub> s that were submitted in amendment 51.	20-AUG-2021	1341755
20-AUG-2021	Y		Amendment # 70. Letter of authorization for a new U.S. agent. This amendment was not in response to an information request.	20-AUG-2021	1342120
20-AUG-2021	Y		Amendment # 71. Response to August 20, 2021, 7th set of PI comments and shell table.	20-AUG-2021	1344590
20-AUG-2021	Y		Amendment # 72. Response to August 20, 2021, clinical IR regarding the shell table.	20-AUG-2021	1344591
20-AUG-2021	Y		Amendment # 73. Response to August 20, 2021, CBER comments regarding label for identification of BLA lots and Dear HCP Letter	20-AUG-2021	1344771
21-AUG-2021	Y		Amendment # 74. Response to August 21, 2021, 8th set of comments on the PI.	23-AUG-2021	1344786
21-AUG-2021	Y		Amendment # 75. Response to August 21, 2021, IR RE PMR <sub>ç</sub> s and PMC <sub>ç</sub> s and final study protocol date for study C4591007	23-AUG-2021	1344787
21-AUG-2021	Y		Amendment # 76. Response to August 21, 2021, IR RE regarding identification of BLA lots/Dear HCP Letter.	23-AUG-2021	1344788
23-AUG-2021	Y		Amendment # 77. Final PI (when compared to the PI received in STN 125.0.74 it was the same EXCEPT Pfizer <sub>ç</sub> s version number at the very end of the PI was changed from LAB-1448-.9 to LAB-1448-1.0).	23-AUG-2021	1346819
24-AUG-2021	Y		Amendment # 78. Final PI which has been revised to include the license number	24-AUG-2021	1350971
07-MAY-2023	Y		Amendment # 20. Response to July 13, 2021 OBE IR to add myocarditis and pericarditis to the PVP.	29-JUL-2021	1230081
07-JUN-2023	Y		Amendment # 21. Response to July 16, 2021 DBSQC IR regarding (b) (4) test methods.	30-JUL-2021	1232318
07-JUN-2023	Y		Amendment # 23. Response to July 26, 2021 clinical IR regarding the disposition of participants in safety populations who experienced pregnancy.	30-JUL-2021	1235714